Evidence map›Paper›PMID 41222192›Full record

Trial reportTranslational vision science & technology2025

Effect of Increased Power and Asphericity of Highly Aspherical Lenslets on Myopia Control Efficacy: A Contralateral Crossover Study.

Rajkumar Nallour Raveendran, Wee Sing Ong, Yee Ling Wong, Stella Jinran Zhan, Chun Fan Lee, Si Ying Lim, Björn Drobe

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Next-Generation Myopia Control Spectacles Hint at Defocus Opponency Circuits in the Retina.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  5. Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rajkumar Nallour RaveendranR&D, Essilor International, affiliate of EssilorLuxottica, Singapore, Singapore.
Wee Sing OngR&D, Essilor International, affiliate of EssilorLuxottica, Singapore, Singapore.
Yee Ling WongR&D, Essilor International, affiliate of EssilorLuxottica, Singapore, Singapore.
Stella Jinran ZhanCentre for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Chun Fan LeeCentre for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Si Ying LimR&D, Essilor International, affiliate of EssilorLuxottica, Singapore, Singapore.
Björn DrobeR&D, Essilor International, affiliate of EssilorLuxottica, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The study aims to evaluate whether the myopia control efficacy of spectacle lenses with Highly Aspherical Lenslet Target (H.A.L.T.) technology could be further improved by a combined increase of power and asphericity of lenslets. Methods: Fifty Singaporean myopic children aged 6 to 10 years were enrolled in a randomized, contralateral, crossover clinical trial. Two different myopia control spectacle lenses were tested: lenses with H.A.L.T. technology and lenses with maximized H.A.L.T. (H.A.L.T. MAX) technology. One group (N = 25) was assigned to wear H.A.L.T. MAX on the right eye and H.A.L.T. on the left eye, and the other group (N = 25) to wear the opposite combination for 6 months. The combinations were switched for the next 6 months. The primary outcome was the change in axial length (AL). Results: At baseline, mean (±SD) AL of eyes wearing H.A.L.T. and H.A.L.T. MAX lenses was 23.97 ± 0.84 and 23.99 ± 0.84 mm. After the first 6 months, mean (±SEM) axial elongation in eyes wearing H.A.L.T. and H.A.L.T. MAX lenses was 0.105 ± 0.016 and 0.043 ± 0.016 mm (P < 0.001), respectively. After the crossover, the corresponding mean AL change was 0.123 ± 0.014 and 0.077 ± 0.013 mm (P < 0.001). The differences in AL change between the two lenses were correlated with faster axial elongation with H.A.L.T. lenses in both phases. Conclusions: Spectacle lenses with H.A.L.T. MAX technology slowed axial elongation more effectively than spectacle lenses with H.A.L.T. technology and might be particularly beneficial for children with faster axial elongation. Translational Relevance: The relationship between the optical characteristics of lenslets and axial elongation offers a new avenue for developing more effective myopia control lenses.

Indexed as

EyeglassesMyopiaRefraction, OcularAxial Length, EyeChildCross-Over StudiesFemaleHumansMaleTreatment OutcomeVisual Acuity

Identifiers

PMID41222192
PMCPMC12614271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.